Canopy Growth Corporation (CGC) vs Enanta Pharmaceuticals, Inc. (ENTA)

A side-by-side comparison of Canopy Growth Corporation and Enanta Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CGC vs ENTA

growth of $100 · dividends reinvested · last 10y
CGC -97.6% (-31.2%/yr)ENTA -52.4% (-7.2%/yr)ENTA compounded faster over this window
Log scale — wide-divergence pair
1101001k10kStart $10020182020202220242026$2$48
CGC ENTA

CGC vs ENTA: by the numbers

  • •CGC is the larger company ($373M vs $366M market cap).
  • •Both run net losses; CGC's is the smaller (-81.04% vs -96.89% net margin).
  • •Both shrank revenue over the past five years; ENTA's decline was smaller (-7.65% vs -12.47% CAGR).

Metrics side by side

Valuation

MetricCGCENTA
P/S ratio1.625.61
P/B ratio0.773.63

Profitability

MetricCGCENTA
Gross margin25.47%98.15%
Operating margin-31.98%-130.65%
Net margin-81.04%-96.89%
ROE-38.57%-62.56%
ROIC-10.85%-24.20%

Growth (annualized)

MetricCGCENTA
Revenue CAGR (5Y)-12.47%-7.65%
Total return CAGR (5Y)-63.36%-26.94%

Frequently asked

Which has grown faster, CGC or ENTA?
Neither grew: over the past five years both shrank revenue, with ENTA's decline the smaller — CGC at a -12.47% CAGR versus ENTA at -7.65%.
How have CGC and ENTA total returns compared?
Over the past 10 years, CGC delivered -31.35% and ENTA delivered -7.11% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.